Skip to main content
  • Transcatheter Versus Surgical Aortic Valve Replacement in Cardiac Amyloidosis

    We read with great interest the article by Khan et al.  that was recently accepted by your journal for publication, regarding the clinical outcome of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with cardiac amyloidosis (CA). However, we would like to raise a few concerns about the data presented in this article.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details